Gregory K. Palm
Director/Miembro de la Junta en Olatec Therapeutics LLC .
Cargos activos de Gregory K. Palm
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Director/Miembro de la Junta | 29/07/2021 | - |
Historial de carrera de Gregory K. Palm
Antiguos cargos conocidos de Gregory K. Palm.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
THE GOLDMAN SACHS GROUP, INC. | Consejero General | 01/05/1992 | - |
Secretario Corporativo | 01/05/1992 | - |
Formación de Gregory K. Palm.
Harvard Business School | Graduate Degree |
Massachusetts Institute of Technology | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
Operativa
General Counsel | 1 |
Corporate Secretary | 1 |
Director/Board Member | 1 |
Sectorial
Finance | 3 |
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
THE GOLDMAN SACHS GROUP, INC. | Finance |
Empresas privadas | 1 |
---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Gregory K. Palm
- Experiencia